Dicerna Pharmaceuticals Inc (DRNA) Stock Analyst Ratings
NASDAQ:DRNA - Nasdaq - Common Stock
ChartMill assigns a Buy % Consensus number of 71% to DRNA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 37.16. This target is -2.78% below the current price.
DRNA was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about DRNA.
In the previous month the buy percentage consensus was at a similar level.
DRNA was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-12-09 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2021-11-19 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2021-11-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-08-11 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2021-08-10 | Chardan Capital | Maintains | Buy |
| 2021-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-09 | Citigroup | Downgrade | Buy -> Neutral |
| 2021-08-06 | RBC Capital | Maintains | Outperform |
| 2021-08-06 | SVB Leerink | Maintains | Outperform |
| 2021-08-06 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2021-08-06 | Truist Securities | Downgrade | Buy -> Hold |
| 2021-08-06 | Goldman Sachs | Maintains | Buy |
| 2021-08-06 | HC Wainwright & Co. | Maintains | Buy |
| 2021-06-23 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-16 | Goldman Sachs | Initiate | Buy |
| 2021-04-08 | SVB Leerink | Maintains | Outperform |
| 2021-03-02 | Chardan Capital | Maintains | Buy |
| 2021-03-02 | HC Wainwright & Co. | Maintains | Buy |